DK1399423T3 - Anthranilsyreamider med heteroarylsulfonyl-sidekæde og deres anvendelse som antiarrhytmiske aktive bestanddele - Google Patents

Anthranilsyreamider med heteroarylsulfonyl-sidekæde og deres anvendelse som antiarrhytmiske aktive bestanddele

Info

Publication number
DK1399423T3
DK1399423T3 DK02745333T DK02745333T DK1399423T3 DK 1399423 T3 DK1399423 T3 DK 1399423T3 DK 02745333 T DK02745333 T DK 02745333T DK 02745333 T DK02745333 T DK 02745333T DK 1399423 T3 DK1399423 T3 DK 1399423T3
Authority
DK
Denmark
Prior art keywords
side chain
active ingredients
acid amides
anthranilic acid
heteroarylsulfonyl
Prior art date
Application number
DK02745333T
Other languages
Danish (da)
English (en)
Inventor
Thomas Boehme
Joachim Brendel
Stefan Peukert
Heinz-Werner Kleemann
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1399423T3 publication Critical patent/DK1399423T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/34Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
DK02745333T 2001-06-12 2002-05-31 Anthranilsyreamider med heteroarylsulfonyl-sidekæde og deres anvendelse som antiarrhytmiske aktive bestanddele DK1399423T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10128331A DE10128331A1 (de) 2001-06-12 2001-06-12 Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
PCT/EP2002/005956 WO2002100825A2 (de) 2001-06-12 2002-05-31 Anthranilsäureamide mit heteroarylsulfonyl-seitenkette und ihre verwendung als antiarrhythmische wirkstoffe

Publications (1)

Publication Number Publication Date
DK1399423T3 true DK1399423T3 (da) 2008-03-17

Family

ID=7687941

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02745333T DK1399423T3 (da) 2001-06-12 2002-05-31 Anthranilsyreamider med heteroarylsulfonyl-sidekæde og deres anvendelse som antiarrhytmiske aktive bestanddele

Country Status (41)

Country Link
US (2) US6903216B2 (es)
EP (1) EP1399423B9 (es)
JP (1) JP4422477B2 (es)
KR (1) KR100863924B1 (es)
CN (1) CN1247544C (es)
AR (1) AR036045A1 (es)
AT (1) ATE378318T1 (es)
AU (1) AU2002316939B2 (es)
BG (1) BG108415A (es)
BR (1) BR0210374A (es)
CA (1) CA2450076C (es)
CO (1) CO5540283A2 (es)
CR (1) CR7140A (es)
CY (1) CY1107427T1 (es)
CZ (1) CZ20033361A3 (es)
DE (2) DE10128331A1 (es)
DK (1) DK1399423T3 (es)
EC (1) ECSP034883A (es)
EE (1) EE05196B1 (es)
ES (1) ES2295360T3 (es)
HK (1) HK1065316A1 (es)
HR (1) HRP20031028A2 (es)
HU (1) HUP0400159A3 (es)
IL (2) IL159247A0 (es)
MA (1) MA27037A1 (es)
MX (1) MXPA03010875A (es)
MY (1) MY138341A (es)
NO (1) NO20035450D0 (es)
NZ (1) NZ530081A (es)
OA (1) OA12631A (es)
PE (1) PE20021066A1 (es)
PL (1) PL364371A1 (es)
PT (1) PT1399423E (es)
RS (1) RS97703A (es)
RU (1) RU2293727C2 (es)
SK (1) SK15222003A3 (es)
TN (1) TNSN03134A1 (es)
TW (1) TWI304400B (es)
UA (1) UA75412C2 (es)
WO (1) WO2002100825A2 (es)
ZA (1) ZA200308520B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
EP1500650A4 (en) * 2002-04-26 2006-08-23 Ishihara Sangyo Kaisha PYRIDINE COMPOUNDS OR SALTS THEREOF AND HERBICIDES CONTAINING SAME
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
DE10312061A1 (de) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit Blockern des IK-Kanals und deren Verwendung zur Behandlung von Vorhofarrhythmien
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
EP1489071A1 (en) * 2003-06-18 2004-12-22 4Sc Ag N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators
PT1651621E (pt) 2003-08-08 2008-09-30 Janssen Pharmaceutica Nv Compostos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de cck2
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
BRPI0516027A (pt) * 2004-09-24 2008-08-19 Janssen Pharmaceutica Nv compostos de sulfonamida
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
NZ572231A (en) * 2006-04-27 2010-12-24 Sanofi Aventis Deutschland Inhibitors of the task-1 and task-3 ion channel
WO2008124524A2 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
WO2011000541A1 (en) * 2009-06-29 2011-01-06 Merz Pharma Gmbh & Co Kgaa Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane
ES2632954T3 (es) 2009-06-29 2017-09-18 Agios Pharmaceuticals, Inc. Derivados de quinolina-8-sulfonamida que tienen una actividad anticancerosa
WO2011010132A1 (en) * 2009-07-21 2011-01-27 Astrazeneca Ab Sustained-release composition comprising compound 600
FR2967674B1 (fr) * 2010-11-23 2012-12-14 Pf Medicament Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (es) 2011-07-01 2018-04-28
WO2013112932A1 (en) 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US9701627B2 (en) * 2014-06-16 2017-07-11 University Of Maryland, Baltimore LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
CN111183129A (zh) * 2017-08-07 2020-05-19 国立大学法人广岛大学 新型邻氨基苯甲酸系化合物、使用了该化合物的Pin1抑制剂、炎症性疾病及癌症的治疗剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155662A1 (en) 1993-12-27 1995-07-06 Fumihiro Ozaki Anthranilic acid derivative
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
DK173062B1 (da) 1996-10-11 1999-12-13 Krueger As I Fremgangsmåde til fjernelse af opløste metaller og/eller metalloider fra et vandigt medium indeholdende samme og med et sto
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
CA2336807C (en) 1998-07-08 2010-04-13 Aventis Pharma Deutschland Gmbh Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
AU754204B2 (en) 1998-09-01 2002-11-07 Bristol-Myers Squibb Company Potassium channel inhibitors and method
IL146513A0 (en) * 1999-06-24 2002-07-25 Smithkline Beecham Corp Macrophage scavenger receptor antagonists
DE19947457A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
US6531495B1 (en) * 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
US20030114499A1 (en) 2003-06-19
PL364371A1 (en) 2004-12-13
CY1107427T1 (el) 2012-12-19
OA12631A (fr) 2006-06-14
KR100863924B1 (ko) 2008-10-17
HUP0400159A3 (en) 2008-10-28
NO20035450D0 (no) 2003-12-08
HUP0400159A2 (hu) 2004-07-28
UA75412C2 (en) 2006-04-17
MXPA03010875A (es) 2004-02-17
ECSP034883A (es) 2004-01-28
HRP20031028A2 (en) 2005-10-31
ES2295360T3 (es) 2008-04-16
CO5540283A2 (es) 2005-07-29
PE20021066A1 (es) 2003-01-21
IL159247A0 (en) 2004-06-01
RU2293727C2 (ru) 2007-02-20
EP1399423A2 (de) 2004-03-24
CR7140A (es) 2004-04-15
PT1399423E (pt) 2008-02-07
CN1247544C (zh) 2006-03-29
TWI304400B (en) 2008-12-21
NZ530081A (en) 2005-07-29
JP4422477B2 (ja) 2010-02-24
BR0210374A (pt) 2004-07-13
RS97703A (en) 2006-12-15
CZ20033361A3 (cs) 2004-05-12
CA2450076C (en) 2010-11-30
SK15222003A3 (sk) 2004-06-08
TNSN03134A1 (en) 2005-12-23
BG108415A (en) 2004-07-30
MA27037A1 (fr) 2004-12-20
ZA200308520B (en) 2004-09-06
KR20040030668A (ko) 2004-04-09
RU2004100302A (ru) 2005-04-10
AR036045A1 (es) 2004-08-04
CN1529695A (zh) 2004-09-15
EE200300558A (et) 2004-02-16
HK1065316A1 (en) 2005-02-18
WO2002100825A3 (de) 2003-12-11
IL159247A (en) 2010-06-16
EP1399423B1 (de) 2007-11-14
JP2004533464A (ja) 2004-11-04
CA2450076A1 (en) 2002-12-19
US6903216B2 (en) 2005-06-07
DE50211213D1 (de) 2007-12-27
EP1399423B9 (de) 2008-02-27
US7235664B2 (en) 2007-06-26
ATE378318T1 (de) 2007-11-15
MY138341A (en) 2009-05-29
US20050137200A1 (en) 2005-06-23
AU2002316939B2 (en) 2006-11-23
WO2002100825A2 (de) 2002-12-19
DE10128331A1 (de) 2002-12-19
EE05196B1 (et) 2009-08-17

Similar Documents

Publication Publication Date Title
DK1399423T3 (da) Anthranilsyreamider med heteroarylsulfonyl-sidekæde og deres anvendelse som antiarrhytmiske aktive bestanddele
NO20034751D0 (no) Antranilsyreamider, deres fremstilling og anvendelse samt preparater
NO20012245L (no) Anthranilsyreamider og anvendelse derav som medikamenter
NO20033565D0 (no) Acylerte indanylaminer og deres anvendelse som farmasöytiske midler
NO20033566D0 (no) Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler
DK1478629T3 (da) N-aryl-2-oxazolidinon-5-carboxamider og deres derivater og deres anvendelse som antibakterielle midler
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
AU2002316939A1 (en) Anthranilic acid amides with a heteroarylsulfonyl side chain, and use thereof as antiarrhythmic active substances
DK1564210T5 (da) 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer
DK1480955T3 (da) O-cyclopropyl-carboxanilider og deres anvendelse som fungicider
DK1246802T3 (da) 4-aminopicolinater og deres anvendelse som herbicider
NO20050830L (no) Acylerte heteroarylkondenserte sykloalkenylaminer og deres anvendelse som farmasoytiske midler
HUP0302845A3 (en) 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20020383L (no) Mutilinderivater og deres anvendelse som anti-bakterielle midler
NO20025357D0 (no) Antranylamider og deres anvendelse som legemidler
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
DK1558595T3 (da) Piperazinyl- og diazapanylbenzamider og -benzthioamider
NO20043580L (no) Quinazolinonderivater og deres bruk som CB agonister
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
DK1525193T3 (da) Acylaminothiazolderivater, deres fremstilling og deres terapeutiske anvendelse
EE200100416A (et) Hargneva ahelaga aminohappe-sõltuvad aminotransferaasinhibiitorid ja nende kasutamine diabeetilise retinopaatia ravis
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
DE60318139D1 (de) Isolator- und Anordnungskonfiguration
NO20030998L (no) Arylpiperazinderivater og deres anvendelse som psykotropiske midler